These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

494 related items for PubMed ID: 34314399

  • 1. Clinical Presentations, Management and Outcomes of Rhino-Orbital-Cerebral Mucormycosis (ROCM) Following COVID-19: A Multi-Centric Study.
    Dave TV, Gopinathan Nair A, Hegde R, Vithalani N, Desai S, Adulkar N, Kamal S, Mittal R, Bradoo RA.
    Ophthalmic Plast Reconstr Surg; ; 37(5):488-495. PubMed ID: 34314399
    [Abstract] [Full Text] [Related]

  • 2. Is mucormycosis the end? A comprehensive management of orbit in COVID associated rhino-orbital-cerebral mucormycosis: preserving the salvageable.
    Keshri A, Mathialagan A, Aishwarya A, Ravisankar, Bhuskute G, Kanaujia V, Singh AK, Singh RK, Dhiman RK, Agarwal R.
    Eur Arch Otorhinolaryngol; 2023 Feb; 280(2):819-827. PubMed ID: 36053359
    [Abstract] [Full Text] [Related]

  • 3. Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India - Collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC), Report 1.
    Sen M, Honavar SG, Bansal R, Sengupta S, Rao R, Kim U, Sharma M, Sachdev M, Grover AK, Surve A, Budharapu A, Ramadhin AK, Tripathi AK, Gupta A, Bhargava A, Sahu A, Khairnar A, Kochar A, Madhavani A, Shrivastava AK, Desai AK, Paul A, Ayyar A, Bhatnagar A, Singhal A, Nikose AS, Bhargava A, Tenagi AL, Kamble A, Nariani A, Patel B, Kashyap B, Dhawan B, Vohra B, Mandke C, Thrishulamurthy C, Sambare C, Sarkar D, Mankad DS, Maheshwari D, Lalwani D, Kanani D, Patel D, Manjandavida FP, Godhani F, Agarwal GA, Ravulaparthi G, Shilpa GV, Deshpande G, Thakkar H, Shah H, Ojha HR, Jani H, Gontia J, Mishrikotkar JP, Likhari K, Prajapati K, Porwal K, Koka K, Dharawat KS, Ramamurthy LB, Bhattacharyya M, Saini M, Christy MC, Das M, Hada M, Panchal M, Pandharpurkar M, Ali MO, Porwal M, Gangashetappa N, Mehrotra N, Bijlani N, Gajendragadkar N, Nagarkar NM, Modi P, Rewri P, Sao P, Patil PS, Giri P, Kapadia P, Yadav P, Bhagat P, Parekh R, Dyaberi R, Chauhan RS, Kaur R, Duvesh RK, Murthy R, Dandu RV, Kathiara R, Beri R, Pandit R, Rani RH, Gupta R, Pherwani R, Sapkal R, Mehta R, Tadepalli S, Fatima S, Karmarkar S, Patil SS, Shah S, Shah S, Shah S, Dubey S, Gandhi S, Kanakpur S, Mohan S, Bhomaj S, Kerkar S, Jariwala S, Sahu S, Tara S, Maru SK, Jhavar S, Sharma S, Gupta S, Kumari S, Das S, Menon S, Burkule S, Nisar SP, Kaliaperumal S, Rao S, Pakrasi S, Rathod S, Biradar SG, Kumar S, Dutt S, Bansal S, Ravani SA, Lohiya S, Ali Rizvi SW, Gokhale T, Lahane TP, Vukkadala T, Grover T, Bhesaniya T, Chawla U, Singh U, Une VL, Nandedkar V, Subramaniam V, Eswaran V, Chaudhry VN, Rangarajan V, Dehane V, Sahasrabudhe VM, Sowjanya Y, Tupkary Y, Phadke Y, members of the Collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC) Study Group.
    Indian J Ophthalmol; 2021 Jul; 69(7):1670-1692. PubMed ID: 34156034
    [Abstract] [Full Text] [Related]

  • 4. Rhino-orbital mucormycosis following COVID-19 in previously non-diabetic, immunocompetent patients.
    Nair AG, Adulkar NG, D'Cunha L, Rao PR, Bradoo RA, Bapaye MM, Kothari A, Dave TV, Shinde CA.
    Orbit; 2021 Dec; 40(6):499-504. PubMed ID: 34338124
    [Abstract] [Full Text] [Related]

  • 5. Outcomes of transcutaneous retrobulbar Amphotericin B (TRAMB) as an adjuvant therapy for rhino-orbital-cerebral mucormycosis (ROCM) following COVID-19.
    Shakrawal J, Sharma V, Goyal A, Kumar D, Meena S, Tiwari S, Jain V, Elhence P, Soni K, Choudhury B, Bhatnagar K, Garg MK, Misra S.
    Int Ophthalmol; 2023 Jun; 43(6):1919-1926. PubMed ID: 36427099
    [Abstract] [Full Text] [Related]

  • 6. Rhino-orbital mucormycosis: Our experiences with clinical features and management in a tertiary care center.
    Singh SP, Rana J, Singh VK, Singh R, Sachan R, Singh S, Jain S.
    Rom J Ophthalmol; 2021 Jun; 65(4):339-353. PubMed ID: 35087975
    [Abstract] [Full Text] [Related]

  • 7. Rise of the phoenix: Mucormycosis in COVID-19 times.
    Ravani SA, Agrawal GA, Leuva PA, Modi PH, Amin KD.
    Indian J Ophthalmol; 2021 Jun; 69(6):1563-1568. PubMed ID: 34011742
    [Abstract] [Full Text] [Related]

  • 8. Analysis of COVID-19-associated rhino-orbital-cerebral mucormycosis patients in a tertiary care center in Northern India.
    Yadav H, Sen S, Nath T, Mazumdar S, Jain A, Verma P, Gupta P.
    Indian J Ophthalmol; 2022 Jun; 70(6):2163-2168. PubMed ID: 35648004
    [Abstract] [Full Text] [Related]

  • 9. Susceptibility of severe COVID-19 patients to rhino-orbital mucormycosis fungal infection in different clinical manifestations.
    Bayram N, Ozsaygılı C, Sav H, Tekin Y, Gundogan M, Pangal E, Cicek A, Özcan İ.
    Jpn J Ophthalmol; 2021 Jul; 65(4):515-525. PubMed ID: 34057620
    [Abstract] [Full Text] [Related]

  • 10. Outcome of transcutaneous retrobulbar injection of liposomal amphotericin B in post-COVID-19 rhino-orbito-cerebral mucormycosis: Our experience.
    Ramamurthy LB, Bhandari R, Kanakpur S, Thejaswini P.
    Indian J Ophthalmol; 2022 Mar; 70(3):1019-1024. PubMed ID: 35225564
    [Abstract] [Full Text] [Related]

  • 11. A fungal epidemic amidst a viral pandemic: Risk factors for development of COVID-19 associated rhino-orbital-cerebral mucormycosis in India.
    Vasanthapuram VH, Gupta R, Adulkar N, Nair AG, Bradoo RA, Hegde R, Singh U, Tadepalli S, Mukherjee B, Kamal S, Alam MS, Rao R, Ananthakrishna S, Backiavathy V, Murthy AK, D'Cunha L, Dudeja G, Joji A, Kiran A, Koka K, Goswami Mukhopadhyay M, Nisar SP, Rao PR, Shinde CA.
    Orbit; 2023 Feb; 42(1):30-41. PubMed ID: 35192435
    [Abstract] [Full Text] [Related]

  • 12. Outcomes and factors affecting them in patients with rhino-orbito-cerebral mucormycosis.
    Kashkouli MB, Abdolalizadeh P, Oghazian M, Hadi Y, Karimi N, Ghazizadeh M.
    Br J Ophthalmol; 2019 Oct; 103(10):1460-1465. PubMed ID: 30514712
    [Abstract] [Full Text] [Related]

  • 13. Adjunctive use of saturated solution of potassium iodide (SSKI) with liposomal amphotericin B (L-AMB) in mucormycosis achieves favorable response, shortened dose and duration of amphotericin: A retrospective study from a COVID-19 tertiary care center.
    Mrig S, Sardana K, Arora P, Narula V, Arora S, Kapoor A, Baruah RR, Sen P, Agarwal S, Sachdeva S, Dewan A, Panesar S.
    Am J Otolaryngol; 2022 Oct; 43(3):103465. PubMed ID: 35429848
    [Abstract] [Full Text] [Related]

  • 14. Rhino-orbital mucormycosis during steroid therapy in COVID-19 patients: A case report.
    Veisi A, Bagheri A, Eshaghi M, Rikhtehgar MH, Rezaei Kanavi M, Farjad R.
    Eur J Ophthalmol; 2022 Jul; 32(4):NP11-NP16. PubMed ID: 33843287
    [Abstract] [Full Text] [Related]

  • 15. Post-COVID-19 rhino-orbito-cerebral mucormycosis: a new addition to challenges in pandemic control.
    Mitra S, Janweja M, Sengupta A.
    Eur Arch Otorhinolaryngol; 2022 May; 279(5):2417-2422. PubMed ID: 34309754
    [Abstract] [Full Text] [Related]

  • 16. Transcutaneous retrobulbar injection of amphotericin B in rhino-orbital-cerebral mucormycosis: a review.
    Nair AG, Dave TV.
    Orbit; 2022 Jun; 41(3):275-286. PubMed ID: 34720026
    [Abstract] [Full Text] [Related]

  • 17. Transcutaneous retrobulbar amphotericin B for rhino-orbital-cerebral mucormycosis: a multi-center retrospective comparative study.
    Dallalzadeh LO, Ediriwickrema LS, Fung SE, Men CJ, Kossler AL, Kupcha AC, Mawn LA, Burkat CN, van Landingham SW, Conger JR, Simmons B, Pham C, Akella SS, Setabutr P, Ho T, Couch SM, Kim JS, Demirci H, Korn BS, Kikkawa DO, Liu CY.
    Orbit; 2024 Feb; 43(1):41-48. PubMed ID: 36880205
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.